Literature DB >> 21512888

Valproic acid and warfarin: an underrecognized drug interaction.

Hyue W Yoon1, Elias A Giraldo, Eelco F M Wijdicks.   

Abstract

BACKGROUND: Drug interactions in the neurosciences intensive care unit (NICU) may involve antiepileptic drugs and warfarin. Most commonly used antiepileptic drugs are either potent hepatic enzyme inducers or inhibitors and they affect the metabolism of warfarin. Valproic acid also displaces warfarin from the protein binding sites resulting in significant INR changes but this type of drug interaction is less well known.
METHODS: Case report.
RESULTS: A 71 year-old female patient with a glioblastoma multiforme presented to the NICU with refractory partial complex seizures. Patient was on warfarin for a prior deep venous thrombosis. After treatment with levetiracetam, seizures recurred and intravenous loading with valproic acid was administered, but resulted in a rapid increase in international normalized ratio (INR) to 7.6. A MRI of the brain showed hemorrhagic tumor, but no new major bleeding.
CONCLUSIONS: With both acidic drugs present, a loading dose of valproic acid may displace warfarin from the protein binding sites resulting in redistribution of warfarin in free active form and lead to a rapid increase in INR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512888     DOI: 10.1007/s12028-011-9544-5

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  9 in total

1.  Antiepileptic drugs and warfarin.

Authors:  S Nizam Ahmed
Journal:  CMAJ       Date:  2008-01-01       Impact factor: 8.262

Review 2.  Human P450 metabolism of warfarin.

Authors:  L S Kaminsky; Z Y Zhang
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

Review 3.  A mechanistic approach to antiepileptic drug interactions.

Authors:  G D Anderson
Journal:  Ann Pharmacother       Date:  1998-05       Impact factor: 3.154

4.  Drug displacement from protein binding: isolation of a redistributional drug interaction in vivo.

Authors:  E G McQueen; W M Wardell
Journal:  Br J Pharmacol       Date:  1971-10       Impact factor: 8.739

5.  Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs.

Authors:  E M Sellers; J Koch-Weser
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

6.  Hypothesized interaction between valproic acid and warfarin.

Authors:  S K Guthrie; A M Stoysich; G Bader; D E Hilleman
Journal:  J Clin Psychopharmacol       Date:  1995-04       Impact factor: 3.153

Review 7.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.

Authors:  Philip N Patsalos; Emilio Perucca
Journal:  Lancet Neurol       Date:  2003-08       Impact factor: 44.182

9.  The binding of acetaminophen, lidocaine, and valproic acid to human milk.

Authors:  David N Bailey; John R Briggs
Journal:  Am J Clin Pathol       Date:  2004-05       Impact factor: 2.493

  9 in total
  3 in total

1.  Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.

Authors:  Lian Sheng Wang; Jing Jing Shang; Shu Ya Shi; Yan Qing Zhang; Jian Lin; Zhi Hua Guo; Yi Chen Wang; Jie Tang; Jie Liu; Ying Zi Liu; Zhi Li; Zhi Rong Tan; Hong Hao Zhou; Hai He Jiang; Hai Tang Xie
Journal:  Eur J Clin Pharmacol       Date:  2012-12-04       Impact factor: 2.953

2.  Evaluation of sodium valproate low dose efficacy in radicular pain management and it's relation with pharmacokinetics parameters.

Authors:  Mona Ghasemian; Mohammad Bagher Owlia; Mohammad Hossein Mosaddegh; Masoud Nakhaie Nejad; Seyed Mojtaba Sohrevardi
Journal:  Biomedicine (Taipei)       Date:  2020-09-01

Review 3.  The critical interaction between valproate sodium and warfarin: case report and review.

Authors:  Chenguang Zhou; Yi Sui; Weijin Zhao; Chunyao Dong; Li Ren; Pingmei Song; Bing Xu; Xiaohong Sun
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-01       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.